Compare stocks

AIMD vs IKT

Ainos, Inc. Common Stock and Inhibikase Therapeutics, Inc. Common Stock

Compare the businesses

Ainos, Inc. Common Stock

Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics. Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data. The company is also giving AI for robotics, smart factories, senior care, and women's health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.

Open AIMD dashboard ↗

Inhibikase Therapeutics, Inc. Common Stock

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

Open IKT dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗